{"id":"W4409256027","doi":"10.1182/blood.2024026216","title":"Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Stanford Cancer Institute; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Seagen; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Medac; Jazz Pharmaceuticals; BeiGene; HistoGenetics; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Gateway for Cancer Research; Doris Duke Charitable Foundation; Amgen; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; Alexion Pharmaceuticals; Mallinckrodt Pharmaceuticals; Astellas Pharma US","keywords":"Medicine; Internal medicine; Multiple myeloma; Clinical trial; Refractory (planetary science); Cohort; Surgery; Oncology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002490554,0.0001435182,0.0003983055,0.0001967878,0.00007650108,0.00001351934,0.0001536614,0.0001350909,0.0005123136],"category_scores_gemma":[0.0003851008,0.0001320223,0.0002077102,0.000282824,0.00008042822,0.00004155173,0.00006843314,0.0001943311,0.00001201316],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009009559,"about_ca_system_score_gemma":0.0003881763,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001846372,"about_ca_topic_score_gemma":0.00003941536,"domain_scores_codex":[0.9987107,0.00003818181,0.0002986597,0.0002945749,0.0003473112,0.000310604],"domain_scores_gemma":[0.9986029,0.0003223809,0.00005978963,0.0005278457,0.0003777836,0.0001092765],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.005043667,0.0007571153,0.02423524,0.001239386,0.000527677,0.00003955192,0.0006721329,0.000002502124,0.8680174,0.0004300478,0.002668134,0.09636718],"study_design_scores_gemma":[0.0185486,0.001772897,0.01060378,0.0002642373,0.0002462826,0.000007491953,0.0005141041,0.00003223802,0.7798464,0.0001910092,0.1878328,0.0001400658],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9676892,0.004546921,0.0005546059,0.000467855,0.0002104048,0.001431829,0.0001503856,0.00009921954,0.02484962],"genre_scores_gemma":[0.9856678,0.0001690995,0.002947576,0.000192117,0.0001322797,0.000104555,0.00005492767,0.0000412391,0.01069039],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1851647,"threshold_uncertainty_score":0.5609475,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02212432035080703,"score_gpt":0.3219916211097771,"score_spread":0.2998673007589701,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}